MindBio Therapeutics, a biopharmaceutical company developing microdoses of psychedelic medicines for psychiatric treatments, has announced that its microdosing formulation MB22001 has achieved 12-month shelf stability at room temperature.
MB22001 is a proprietary, self-titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home use by patients with depression. As of October 2024, MB22001 is being tested in multiple Phase IIB clinical trials.
The 12-month shelf stability ensures that the product remains safe and effective for patients during this period, meeting key regulatory requirements for product quality and patient safety.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.